724 related articles for article (PubMed ID: 18786706)
1. Physician investment in the health care industry: a concern.
Watts C
Surg Neurol; 2009 Oct; 72(4):401-2. PubMed ID: 18786706
[No Abstract] [Full Text] [Related]
2. Physician 'self-referral': what do the studies really show?
Steeley B
Internist; 1992 Feb; 33(2):9-11. PubMed ID: 10118321
[No Abstract] [Full Text] [Related]
3. Medtronic "fusiongate".
Boehm FH
Surg Neurol; 2006 Nov; 66(5):551. PubMed ID: 17084214
[No Abstract] [Full Text] [Related]
4. Doctors and the drug industry: reader feedback.
Nardone DA
Am J Med; 2005 Oct; 118(10):1176-7; author reply 1177. PubMed ID: 16194658
[No Abstract] [Full Text] [Related]
5. The devil in the detail(ing).
Morreim H
Am J Bioeth; 2010 Jan; 10(1):15-7. PubMed ID: 20077328
[No Abstract] [Full Text] [Related]
6. Huddle gets it right, most docs don't.
Rubin PH
Am J Bioeth; 2010 Jan; 10(1):17-9. PubMed ID: 20077329
[No Abstract] [Full Text] [Related]
7. Response to open peer commentaries on "The pitfalls of deducing ethics from economics: why the Association of American Medical Colleges is wrong about pharmaceutical detailing".
Huddle TS
Am J Bioeth; 2010 Jan; 10(1):W1-3. PubMed ID: 20077322
[No Abstract] [Full Text] [Related]
8. The details are in the field.
Schwab AP
Am J Bioeth; 2010 Jan; 10(1):19-21. PubMed ID: 20077330
[No Abstract] [Full Text] [Related]
9. Why academic medical centers should ban drug company gifts to individuals.
Strong C
Am J Bioeth; 2010 Jan; 10(1):13-5. PubMed ID: 20077327
[No Abstract] [Full Text] [Related]
10. Drug detailers, professionalism, and prudence.
Brody H
Am J Bioeth; 2010 Jan; 10(1):9-10. PubMed ID: 20077325
[No Abstract] [Full Text] [Related]
11. Public disclosure of conflicts of interest: moving the policy debate forward.
Campbell EG
Arch Intern Med; 2010 Apr; 170(8):667. PubMed ID: 20421548
[No Abstract] [Full Text] [Related]
12. Avoiding over-deterrence in managing physicians' relationships with industry.
Stell LK
Am J Bioeth; 2010 Jan; 10(1):27-9. PubMed ID: 20077334
[No Abstract] [Full Text] [Related]
13. Contact with pharmaceutical representatives: where does prudence lead?
Appelbaum PS
Am J Bioeth; 2010 Jan; 10(1):11-3. PubMed ID: 20077326
[No Abstract] [Full Text] [Related]
14. Financing of physician ventures.
DeNelsky S
Iowa Med; 1995 May; 85(5):202-5. PubMed ID: 7607830
[No Abstract] [Full Text] [Related]
15. The pitfalls of misreading: what does "industry funding of medical education" actually say?
Spielman B
Am J Bioeth; 2010 Jan; 10(1):24-5. PubMed ID: 20077332
[No Abstract] [Full Text] [Related]
16. The AAMC exhibits the behavior it condemns.
Stossel TP
Am J Bioeth; 2010 Jan; 10(1):26-7. PubMed ID: 20077333
[No Abstract] [Full Text] [Related]
17. Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system.
Rodwin MA
Am J Law Med; 1995; 21(2-3):241-57. PubMed ID: 8571977
[No Abstract] [Full Text] [Related]
18. Doctors and the drug industry: reader feedback.
Warrier R; Houghton B
Am J Med; 2005 Oct; 118(10):1175-6; author reply 1176. PubMed ID: 16194656
[No Abstract] [Full Text] [Related]
19. Marketing of antipsychotic drugs targeted doctors of Medicaid patients, report says.
Roehr B
BMJ; 2012 Oct; 345():e6633. PubMed ID: 23033376
[No Abstract] [Full Text] [Related]
20. [Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry].
Hebebrand J; Blanz B; Herpertz-Dahlmann B; Lehmkuhl G
Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):133-8. PubMed ID: 22774235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
